Archive
Proactive news snapshot: Galileo Resources, ValiRx, ITM Power …
A glance at some of the day's highlights from the Proactive Investors newswire
Company
ValiRx PLC
LON:VAL
ValiRx is a drug development company, which focuses on the translation of scientific innovation into clinical candidates for cancer, related conditions and women’s health. The company's specialised business model connects science, finance and commerce to accelerate early-stage drug development. It identifies proprietary and novel drug candidates with the potential to improve patient lives, providing the expertise and investment required for optimised development and value creation.
310 stories · page 7 of 16
D4t4 jumps as two ‘biggest ever contracts’ boost revenues and profits
The medical diagnostics group is planning on closing its sites in India and Germany as it looks to get back to profitability from a smaller revenue base
ValiRx chairman upbeat on the potential of two lead compounds
Last year saw the company make significant progress with VAL201 and VAL401
Archive
Proactive news snapshot: Amur Minerals, Strategic Minerals, Bloomsbury Publishing …
A glance at some of the day's highlights from the Proactive Investors newswire
LiDCO Group shares fall as it ends third party UK distribution agreement
A look at some of the biggest risers and fallers in London on Tuesday
ValiRx receives US patent protection for exciting lead cancer drug
The protection covers the molecule and a “wide variety of derivatives, modifications and analogues of the compounds and their mode of action”
Archive
Proactive news snapshot: Thor Mining, Papua Mining, Range Resources …
A glance at some of the day's highlights from the Proactive Investors newswire
Archive
Proactive news snapshot: Instem, Thor Mining, Anglo Asian Mining …
A glance at some of the day's highlights from the Proactive Investors newswire
Investments and investor services
Speculators keep GKN shares higher, FTSE 100 miners under fire
A look at some of the top risers and fallers in London today
ValiRx releases more positive data from VAL401 phase II lung cancer trial
The latest data from the trial shows that VAL401 had a positive impact on patients’ quality of life and doesn’t cause immune suppression like chemotherapy, for example
Investments and investor services
FTSE 100 closes lower as miners prove a drag
London’s blue-chip benchmark closed around 13 points lower on the day at 7,755
Archive
Proactive news snapshot: Lombard Risk Management, ValiRx, Connemara Mining …
A glance at some of the day's highlights from the Proactive Investors newswire
Boohoo shares edge lower as margins ease over Christmas trading period
A look at some of the top risers and fallers in London today
ValiRx given US patent boost for its lead therapeutic compound
VAL201 is currently in a Phase I/II study that is assessing safety and tolerability and its effect in the treatment of prostate cancer and other solid tumours
FTSE 100 closes at third successive new high but retailers lag
FTSE 100 closed in London around 14 points higher at 7,762
ValiRx puts convertible loan note facility with Yorkville to bed
ValiRx confirms that there are no further obligations existing between itself and Yorkville
Westminster Group top London riser on Middle East opportunity update
Proactive takes a look at what's moving on a half day of London trading
Archive
Proactive news snapshot: Westminster Group, Motif Bio, Tavistock Investments, Valtrex …
A glance at some of the day's highlights from the Proactive Investors newswire
ValiRx brings in £1mln from share sale which will be used to help fund trial of prostate cancer drug
The biotechnology company issued just over 23.5mln new shares
FTSE 100 reverses and closes in red as City packs up for Christmas
The Office for National Statistics (ONS) says that UK GDP grew by 1.7% in the three months to September